MINI FUTURE SHORT - ELI LILLY & CO | Market Closed - Swiss Exchange 08:50:00 28/05/2024 pm IST | ||
| 0.56 CHF | +9.80% |
|
| Current month | -54.10% | ||
| 1 month | -54.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.56 | +9.80% |
| 27/24/27 | 0.51 | -1.92% |
| 24/24/24 | 0.52 | +4.00% |
| 23/24/23 | 0.5 | -16.67% |
| 22/24/22 | 0.6 | +5.26% |
Delayed Quote Swiss Exchange
Last update May 28, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| VXSABP | |
| ISIN | CH1332894398 |
| Date issued | 22/03/2024 |
| Strike | 865.9 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.31 CHF |
|---|---|
| Lowest since issue | 0.5 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.75% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- VXSABP Certificat
